Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors Pharmaceuticals 2009, 2, 118-124Reportar como inadecuado




Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors Pharmaceuticals 2009, 2, 118-124 - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Department of Internal Medicine and Cardiovascular Diseases, University Hospital -Paolo Giaccone-, University of Palermo, Italy





*

Author to whom correspondence should be addressed.



Note: In lieu of an abstract, this is an excerpt from the first page.

Excerpt In the published version -Paladini et al. reported that aliskiren 300 mg provided a sustained BP-lowering effect beyond the 24-h dosing interval, with a significantly smaller loss of BP-lowering effect in the 24-48 h period after dose than irbesartan 300 mg or ramipril 10 mg 25-. Paladini et al. should be Palatini et al., and the cited reference number should be 10, not 25

In the sentence -Early data suggest a role for aliskiren in preventing end-organ damage but, considering the ONTARGET results with an ACE-I-ARB combination, outcome studies are needed before the use of aliskiren can be recommended in combination with other RAS inhibitors 18–30- one more citation number was added 5, so the revised sentence is -Early data suggest a role for aliskiren in preventing end-organ damage but, considering the ONTARGET results with an ACE-I-ARB combination, outcome studies are needed before the use of aliskiren can be recommended in combination with other RAS inhibitors 5,18–30-.

. View Full-Text





Autor: Salvatore Novo * , Giovanni Fazio, Elena Raccuglia, Antonino Mignano and Giuseppina Novo

Fuente: http://mdpi.com/



DESCARGAR PDF




Documentos relacionados